Prostaglandin EP2 receptor: Novel therapeutic target for human cancers (Review)

Sun,Xiaoting; Li,Qi

doi:10.3892/ijmm.2018.3744

Prostaglandin EP2 receptor: Novel therapeutic target for human cancers (Review)

Authors:
- Xiaoting Sun
- Qi Li
View Affiliations

Affiliations: Department of Medical Oncology and Cancer Institute of Integrative Medicine, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, P.R. China
Published online on: June 26, 2018 https://doi.org/10.3892/ijmm.2018.3744
Pages: 1203-1214

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostaglandin E2 (PGE2) receptor 2 subtype (EP2), which is a metabolite of arachidonic acid that binds with and regulates cellular responses to PGE2, is associated with numerous physiological and pathological events in a wide range of tissues. As a stimulatory G protein‑coupled receptor, PGE2‑induced EP2 activation can activate adenylate cyclase, leading to increased cytoplasmic cAMP levels and activation of protein kinase A. The EP2 receptor can also activate the glycogen synthase kinase 3β and β‑catenin pathways. The present study aimed to review the roles of the EP2 receptor in tumor development, including immunity, chronic inflammation, angiogenesis, metastasis and multidrug resistance. Furthermore, the involvement of the EP2 receptor signaling pathway in cancer was discussed. Understanding the role and mechanisms of action of the EP2 receptor, and its importance in targeted therapy, may help identify novel methods to improve management of numerous types of cancer.

View Figures

View References

1	Cui FB, Huang DF, Zhang FL, Gao EY, Zhang Y, Cao YM, Ding S, Wang Y, Cao QS and Cao XM: Investigation on the regulatory effect of PGE2 on ESCC cells through the trans-activation of EGFR by EP2 and the relevant mechanism. Eur Rev Med Pharmacol Sci. 21:5668–5676. 2017.PubMed/NCBI
2	Asting AG, Iresjö BM, Nilsberth C, Smedh U and Lundholm K: Host knockout of E-prostanoid 2 receptors reduces tumor growth and causes major alterations of gene expression in prostaglandin E2-producing tumors. Oncol Lett. 13:476–482. 2017. View Article : Google Scholar : PubMed/NCBI
3	Flórez-Grau G, Cabezón R, Borgman KJE, España C, Lozano JJ, Garcia-Parajo MF and Benitez-Ribas D: Up-regulation of EP2 and EP3 receptors in human tolerogenic dendritic cells boosts the immunosuppressive activity of PGE2. J Leukoc Biol. 102:881–895. 2017. View Article : Google Scholar
4	Maric J, Ravindran A, Mazzurana L, Björklund ÅK, Van Acker A, Rao A, Friberg D, Dahlén SE, Heinemann A, Konya V and Mjösberg J: Prostaglandin E2 suppresses human group 2 innate lymphoid cell function. J Allergy Clin Immunol. 141:1761–1773. 2018. View Article : Google Scholar :
5	Hsu HH, Lin YM, Shen CY, Shibu MA, Li SY, Chang SH, Lin CC, Chen RJ, Viswanadha VP, Shih HN and Huang CY: Prostaglandin E2-induced COX-2 expressions via EP2 and EP4 signaling pathways in human LoVo colon cancer cells. Int J Mol Sci. 18:pii: E1132. 2017. View Article : Google Scholar
6	Gong WH, Zhao N, Zhang ZM, Zhang YX, Yan L and Li JB: The inhibitory effect of resveratrol on COX-2 expression in human colorectal cancer: A promising therapeutic strategy. Eur Rev Med Pharmacol Sci. 21:1136–1143. 2017.PubMed/NCBI
7	Wehbi VL and Taskén K: Molecular mechanisms for cAMP-mediated immunoregulation in t cells-role of anchored protein kinase a signaling units. Front Immunol. 7:2222016. View Article : Google Scholar
8	Shishikura K, Horiuchi T, Sakata N, Trinh DA, Shirakawa R, Kimura T, Asada Y and Horiuchi H: Prostaglandin E2 inhibits neutrophil extracellular trap formation through production of cyclic AMP. Br J Pharmacol. 173:319–331. 2016. View Article : Google Scholar
9	Lee SE, Lim C, Kim H and Cho S: A study of the anti-inflammatory effects of the ethyl acetate fraction of the methanol extract of forsythiae fructus. Afr J Tradit Complement Altern Med. 13:102–113. 2016.
10	Xu L, Stevens J, Hilton MB, Seaman S, Conrads TP, Veenstra TD, Logsdon D, Morris H, Swing DA, Patel NL, et al: COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci Transl Med. 6:242ra2842014. View Article : Google Scholar
11	Al-Taei S, Salimu J, Spary LK, Clayton A, Lester JF and Tabi Z: Prostaglandin E₂-mediated adenosinergic effects on CD14⁺ cells: Self-amplifying immunosuppression in cancer. Oncoimmunology. 6:e12683082016. View Article : Google Scholar
12	Fan Y, Wang Y and Wang K: Prostaglandin E2 stimulates normal bronchial epithelial cell growth through induction of c-Jun and PDK1, a kinase implicated in oncogenesis. Respir Res. 16:1492015. View Article : Google Scholar : PubMed/NCBI
13	O'Callaghan G and Houston A: Prostaglandin E2 and the EP receptors in malignancy: Possible therapeutic targets? Br J Pharmacol. 172:5239–5250. 2015. View Article : Google Scholar : PubMed/NCBI
14	Kuo KT, Wang HW, Chou TY, Hsu WH, Hsu HS, Lin CH and Wang LS: Prognostic role of PGE2 receptor EP2 in esophageal squamous cell carcinoma. Ann Surg Oncol. 16:352–360. 2009. View Article : Google Scholar
15	Edwards TL, Shrubsole MJ, Cai Q, Li G, Dai Q, Rex DK, Ulbright TM, Fu Z, Murff HJ, Smalley W, et al: A study of prostaglandin pathway genes and interactions with current nonsteroidal anti-inflammatory drug use in colorectal adenoma. Cancer Prev Res (Phila). 5:855–863. 2012. View Article : Google Scholar
16	Tian M and Schiemann WP: PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis. FASEB J. 24:1105–1116. 2010. View Article : Google Scholar :
17	Yu L, Wu WK, Li ZJ, Li HT, Wu YC and Cho CH: Prostaglandin E(2) promotes cell proliferation via protein kinase C/extracellular signal regulated kinase pathway-dependent induction of c-Myc expression in human esophageal squamous cell carcinoma cells. Int J Cancer. 125:2540–2546. 2009. View Article : Google Scholar : PubMed/NCBI
18	Trzaskowski B, Latek D, Yuan S, Ghoshdastider U, Debinski A and Filipek S: Action of molecular switches in GPCRs - theoretical and experimental studies. Curr Med Chem. 19:1090–1109. 2012. View Article : Google Scholar :
19	King N, Hittinger CT and Carroll SB: Evolution of key cell signaling and adhesion protein families predates animal origins. Science. 301:361–363. 2003. View Article : Google Scholar : PubMed/NCBI
20	Liu X, Ahn S, Kahsai AW, Meng KC, Latorraca NR, Pani B, Venkatakrishnan AJ, Masoudi A, Weis WI, Dror RO, et al: Mechanism of intracellular allosteric β2AR antagonist revealed by X-ray crystal structure. Nature. 548:480–484. 2017. View Article : Google Scholar : PubMed/NCBI
21	Engelhardt S and Rochais F: G proteins: More than transducers of receptor-generated signals? Circ Res. 100:1109–1111. 2007. View Article : Google Scholar : PubMed/NCBI
22	Gilman AG: G proteins: Transducers of receptor-generated signals. Annu Rev Biochem. 56:615–649. 1987. View Article : Google Scholar : PubMed/NCBI
23	Kinoshita A, Higashino M, Yoshida K, Aratani Y, Kakuuchi A, Hanada K, Takeda H, Naganawa A, Matsuya H and Ohmoto K: Synthesis and evaluation of a potent, well-balanced EP2/EP3 dual agonist. Bioorg Med Chem. 26:200–214. 2018. View Article : Google Scholar
24	Wang J, Zhang L, Kang D, Yang D and Tang Y: Activation of PGE2/EP2 and PGE2/EP4 signaling pathways positively regulate the level of PD-1 in infiltrating CD8⁺ T cells in patients with lung cancer. Oncol Lett. 15:552–558. 2018.
25	Ota H, Katanosaka K, Murase S, Furuyashiki T, Narumiya S and Mizumura K: EP2 receptor plays pivotal roles in generating mechanical hyperalgesia after lengthening contractions. Scand J Med Sci Sports. 28:826–833. 2018. View Article : Google Scholar
26	Wang S, Xie L, Zhang Y, Xu P and Liu A: Expression of prostaglandin E₂ receptors in acquired middle ear cholesteatoma. Clin Exp Otorhinolaryngol. 11:17–22. 2018. View Article : Google Scholar
27	Dinç E, Dursun Ö, Yilmaz B, Vatansever M, Sari AA, Yıldırım Ö and Adıgüzel U: Expression of prostaglandin E2 receptor subtypes in human pterygium and normal conjunctiva: Immunohistochemical study. Int Ophthalmol. Jul 10–2017.Epub ahead of print.
28	Yu Y and Chadee K: Prostaglandin E2 stimulates IL-8 gene expression in human colonic epithelial cells by a posttranscriptional mechanism. J Immunol. 161:3746–3752. 1998.PubMed/NCBI
29	Nakayama T, Mutsuga N, Yao L and Tosato G: Prostaglandin E2 promotes degranulation-independent release of MCP-1 from mast cells. J Leukoc Biol. 79:95–104. 2006. View Article : Google Scholar
30	Weller CL, Collington SJ, Hartnell A, Conroy DM, Kaise T, Barker JE, Wilson MS, Taylor GW, Jose PJ and Williams TJ: Chemotactic action of prostaglandin E2 on mouse mast cells acting via the PGE2 receptor 3. Proc Natl Acad Sci USA. 104:11712–11717. 2007. View Article : Google Scholar : PubMed/NCBI
31	Margeta-Mitrovic M, Jan YN and Jan LY: A trafficking checkpoint controls GABA(B) receptor heterodimerization. Neuron. 27:97–106. 2000. View Article : Google Scholar : PubMed/NCBI
32	Malty RH, Hudmon A, Fehrenbacher JC and Vasko MR: Long-term exposure to PGE2 causes homologous desensitization of receptor-mediated activation of protein kinase A. J Neuroinflammation. 13:1812016. View Article : Google Scholar : PubMed/NCBI
33	Shibuya I, Setiadji SV, Ibrahim N, Harayama N, Maruyama T, Ueta Y and Yamashita H: Involvement of postsynaptic EP4 and presynaptic EP3 receptors in actions of prostaglandin E2 in rat supraoptic neurones. J Neuroendocrinol. 14:64–72. 2002. View Article : Google Scholar : PubMed/NCBI
34	Su Y, Jackson EK and Gorelik E: Receptor desensitization and blockade of the suppressive effects of prostaglandin E(2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes. Cancer Immunol Immunother. 60:111–122. 2011. View Article : Google Scholar
35	Aoki T and Narumiya S: Prostaglandin E₂-EP2 signaling as a node of chronic inflammation in the colon tumor microenvironment. Inflamm Regen. 37:42017. View Article : Google Scholar
36	Salinas-Parra N, Reyes-Martinez C, Prieto MC and Gonzalez AA: Prostaglandin E2 induces prorenin-dependent activation of (Pro) renin receptor and upregulation of cyclooxygenase-2 in collecting duct cells. Am J Med Sci. 354:310–318. 2017. View Article : Google Scholar : PubMed/NCBI
37	Byun JY, Youn YS, Lee YJ, Choi YH, Woo SY and Kang JL: Interaction of apoptotic cells with macrophages upregulates COX-2/PGE2 and HGF expression via a positive feedback loop. Mediators Inflamm. 2014:4635242014. View Article : Google Scholar : PubMed/NCBI
38	Baba Y, Nosho K, Shima K, Goessling W, Chan AT, Ng K, Chan JA, Giovannucci EL, Fuchs CS and Ogino S: PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev. 19:822–831. 2010. View Article : Google Scholar : PubMed/NCBI
39	Castellone MD, Teramoto H, Williams BO, Druey KM and Gutkind JS: Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science. 310:1504–1510. 2005. View Article : Google Scholar : PubMed/NCBI
40	Hsu HH, Chen MC, Day CH, Lin YM, Li SY, Tu CC, Padma VV, Shih HN, Kuo WW and Huang CY: Thymoquinone suppresses migration of LoVo human colon cancer cells by reducing prostaglandin E2 induced COX-2 activation. World J Gastroenterol. 23:1171–1179. 2017. View Article : Google Scholar : PubMed/NCBI
41	Lian S, Xia Y, Ung TT, Khoi PN, Yoon HJ, Lee SG, Kim KK and Jung YD: Prostaglandin E₂ stimulates urokinase-type plasminogen activator receptor via EP2 receptor-dependent signaling pathways in human AGS gastric cancer cells. Mol Carcinog. 56:664–680. 2017. View Article : Google Scholar
42	Merz C, von Mässenhausen A, Queisser A, Vogel W, Andrén O, Kirfel J, Duensing S, Perner S and Nowak M: IL-6 overexpression in ERG-positive prostate cancer is mediated by prostaglandin receptor EP2. Am J Pathol. 186:974–984. 2016. View Article : Google Scholar : PubMed/NCBI
43	Zang S, Ma X, Wu Y, Liu W, Cheng H, Li J, Liu J and Huang A: PGE2 synthesis and signaling in malignant transformation and progression of human hepatocellular carcinoma. Hum Pathol. 63:120–127. 2017. View Article : Google Scholar : PubMed/NCBI
44	Koh SJ, Kim JM, Kim IK, Ko SH and Kim JS: Anti-inflammatory mechanism of metformin and its effects in intestinal inflammation and colitis-associated colon cancer. J Gastroenterol Hepatol. 29:502–510. 2014. View Article : Google Scholar : PubMed/NCBI
45	Bonfill-Teixidor E, Otxoa-de-Amezaga A, Font-Nieves M, Sans-Fons MG and Planas AM: Differential expression of E-type prostanoid receptors 2 and 4 in microglia stimulated with lipopolysaccharide. J Neuroinflammation. 14:32017. View Article : Google Scholar : PubMed/NCBI
46	Huynh K: Inflammation: Targeting inflammatory pathways to treat atherosclerosis and cancer. Nat Rev Cardiol. 14:6292017. View Article : Google Scholar : PubMed/NCBI
47	Liu Y, Fang S, Li X, Feng J, Du J, Guo L, Su Y, Zhou J, Ding G, Bai Y, et al: Aspirin inhibits LPS-induced macrophage activation via the NF-κB pathway. Sci Rep. 7:115492017. View Article : Google Scholar
48	Kang X, Qiu J, Li Q, Bell KA, Du Y, Jung DW, Lee JY, Hao J and Jiang J: Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype. Sci Rep. 7:94592017. View Article : Google Scholar : PubMed/NCBI
49	Gill SK, Yao Y, Kay LJ, Bewley MA, Marriott HM and Peachell PT: The anti-inflammatory effects of PGE2 on human lung macrophages are mediated by the EP4 receptor. Br J Pharmacol. 173:3099–3109. 2016. View Article : Google Scholar : PubMed/NCBI
50	Kawahara K, Hohjoh H, Inazumi T, Tsuchiya S and Sugimoto Y: Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors. Biochim Biophys Acta. 1851:414–421. 2015. View Article : Google Scholar
51	Jiang J, Quan Y, Ganesh T, Pouliot WA, Dudek FE and Dingledine R: Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proc Natl Acad Sci USA. 110:3591–3596. 2013. View Article : Google Scholar : PubMed/NCBI
52	Hooper KM, Yen JH, Kong W, Rahbari KM, Kuo PC, Gamero AM and Ganea D: Prostaglandin E2 Inhibition of IL-27 Production in Murine Dendritic Cells: A novel mechanism that involves IRF1. J Immunol. 198:1521–1530. 2017. View Article : Google Scholar : PubMed/NCBI
53	Li S, Xu X, Jiang M, Bi Y, Xu J and Han M: Lipopolysaccharide induces inflammation and facilitates lung metastasis in a breast cancer model via the prostaglandin E2-EP2 pathway. Mol Med Rep. 11:4454–4462. 2015. View Article : Google Scholar : PubMed/NCBI
54	Li X, Su Y, Hua X, Xie C, Liu J, Huang Y, Zhou L, Zhang M, Li X and Gao Z: Levels of hepatic Th17 cells and regulatory T cells upregulated by hepatic stellate cells in advanced HBV-related liver fibrosis. J Transl Med. 15:752017. View Article : Google Scholar : PubMed/NCBI
55	Fennekohl A, Lucas M and Püschel GP: Induction by interleukin 6 of G(s)-coupled prostaglandin E(2) receptors in rat hepatocytes mediating a prostaglandin E(2)-dependent inhibition of the hepatocyte's acute phase response. Hepatology. 31:1128–1134. 2000. View Article : Google Scholar : PubMed/NCBI
56	Kabashima K, Nagamachi M, Honda T, Nishigori C, Miyachi Y, Tokura Y and Narumiya S: Prostaglandin E2 is required for ultraviolet B-induced skin inflammation via EP2 and EP4 receptors. Lab Invest. 87:49–55. 2007. View Article : Google Scholar
57	Prasad R and Katiyar SK: Ultraviolet radiation-induced inflammation activates β-catenin signaling in mouse skin and skin tumors. Int J Oncol. 44:1199–1206. 2014. View Article : Google Scholar : PubMed/NCBI
58	Prasad R and Katiyar SK: Prostaglandin E2 Promotes UV radiation-induced immune suppression through DNA hyper-methylation. Neoplasia. 15:795–804. 2013. View Article : Google Scholar : PubMed/NCBI
59	Ma X, Aoki T, Tsuruyama T and Narumiya S: Definition of prostaglandin E2-EP2 signals in the colon tumor microenvironment that amplify inflammation and tumor growth. Cancer Res. 75:2822–2832. 2015. View Article : Google Scholar : PubMed/NCBI
60	Shehzad A, Ul Islam S, Lee J and Lee YS: Prostaglandin E2 reverses curcumin-induced inhibition of survival signal pathways in human colorectal carcinoma (HCT-15) cell lines. Mol Cells. 37:899–906. 2014. View Article : Google Scholar : PubMed/NCBI
61	Wang D, Huang S, Yuan X, Liang J, Xu R, Yao G, Feng X and Sun L: The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. Cell Mol Immunol. 14:423–431. 2017. View Article : Google Scholar :
62	Lejeune M, Moreau F and Chadee K: Loss of EP2 receptor subtype in colonic cells compromise epithelial barrier integrity by altering claudin-4. PLos One. 9:e1132702014. View Article : Google Scholar : PubMed/NCBI
63	Trésfier A, Musnier A, Landomiel F, Bourquard T, Boulo T, Ayoub MA, León K, Bruneau G, Chevalier M, Durand G, et al: G protein-dependent signaling triggers a β-arrestin-scaffolded p70S6K/rpS6 module that controls 5'TOP mRNA translation. FASEB J. 32:1154–1169. 2018. View Article : Google Scholar
64	Kaul V, Bhattacharya D, Singh Y, Van Kaer L, Peters-Golden M, Bishai WR and Das G: An important role of prostanoid receptor EP2 in host resistance to Mycobacterium tuberculosis infection in mice. J Infect Dis. 206:1816–1825. 2012. View Article : Google Scholar : PubMed/NCBI
65	Qian X, Zhang J and Liu J: Tumor-secreted PGE2 inhibits CCL5 production in activated macrophages through cAMP/PKA signaling pathway. J Biol Chem. 286:2111–2120. 2011. View Article : Google Scholar :
66	Leander R and Friedman A: Modulation of the cAMP response by Gαi and Gβγ: A computational study of G protein signaling in immune cells. Bull Math Biol. 76:1352–1375. 2014. View Article : Google Scholar : PubMed/NCBI
67	Sreeramkumar V, Hons M, Punzón C, Stein JV, Sancho D, Fresno M and Cuesta N: Efficient T-cell priming and activation requires signaling through prostaglandin E2 (EP) receptors. Immunol Cell Biol. 94:39–51. 2016. View Article : Google Scholar
68	Mao Y, Sarhan D, Steven A, Seliger B, Kiessling R and Lundqvist A: Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin Cancer Res. 20:4096–4106. 2014. View Article : Google Scholar : PubMed/NCBI
69	Yang L, Yamagata N, Yadav R, Brandon S, Courtney RL, Morrow JD, Shyr Y, Boothby M, Joyce S, Carbone DP and Breyer RM: Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest. 111:727–735. 2003. View Article : Google Scholar : PubMed/NCBI
70	Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL and Lou Y: Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol. 11:82018. View Article : Google Scholar : PubMed/NCBI
71	Fujimoto Y, Iwagaki H, Ozaki M, Ogino T, Murata H, Sun DS, Sadamori H, Takahashi HK, Tanaka N and Yagi T: Involvement of prostaglandin receptors (EPR2-4) in in vivo immunosuppression of PGE2 in rat skin transplant model. Int Immunopharmacol. 5:1131–1139. 2005. View Article : Google Scholar : PubMed/NCBI
72	Bonanno A, Albano GD, Siena L, Montalbano AM, Riccobono L, Anzalone G, Chiappara G, Gagliardo R, Profita M and Sala A: Prostaglandin E₂ possesses different potencies in inducing Vascular Endothelial Growth Factor and Interleukin-8 production in COPD human lung fibroblasts. Prostaglandins Leukot Essent Fatty Acids. 106:11–18. 2016. View Article : Google Scholar : PubMed/NCBI
73	Wiktorowska-Owczarek A and Owczarek J: The effect of hypoxia on PGE2-stimulated cAMP generation in HMEC-1. Cell Mol Biol Lett. 20:213–221. 2015. View Article : Google Scholar : PubMed/NCBI
74	Aoyagi T, Newstead MW, Zeng X, Nanjo Y, Peters-Golden M, Kaku M and Standiford TJ: Interleukin-36γ and IL-36 receptor signaling mediate impaired host immunity and lung injury in cytotoxic Pseudomonas aeruginosa pulmonary infection: Role of prostaglandin E2. PLos Pathog. 13:e10067372017. View Article : Google Scholar
75	Takahashi T, Uehara H and Izumi K: Inhibitory effect of soluble EP2 receptor on ovarian tumor growth in nude mice and utility of TMPRSS4 as a combinatorial molecular target. Int J Oncol. 43:416–424. 2013.PubMed/NCBI
76	Cheng SY, Zhang H, Zhang M, Xia SK, Bai XM, Zhang L, Ma J, Rong R, Wang YP, Du MZ, et al: Prostaglandin E₂ receptor EP2 mediates Snail expression in hepatocellular carcinoma cells. Oncol Rep. 31:2099–2106. 2014. View Article : Google Scholar : PubMed/NCBI
77	Sobhani N, Roviello G, Corona SP, Scaltriti M, Ianza A, Bortul M, Zanconati F and Generali D: The prognostic value of PI3K mutational status in breast cancer: A meta-analysis. J Cell Biochem. 119:4287–4292. 2018. View Article : Google Scholar : PubMed/NCBI
78	Ma W and St-Jacques B: Signalling transduction events involved in agonist-induced PGE2/EP4 receptor externalization in cultured rat dorsal root ganglion neurons. Eur J Pain. 22:845–861. 2018. View Article : Google Scholar : PubMed/NCBI
79	Regan JW: EP2 and EP4 prostanoid receptor signaling. Life Sci. 74:143–153. 2003. View Article : Google Scholar : PubMed/NCBI
80	Allison SE, Petrovic N, Mackenzie PI and Murray M: Pro-migratory actions of the prostacyclin receptor in human breast cancer cells that overexpress cyclooxygenase-2. Biochem Pharmacol. 96:306–314. 2015. View Article : Google Scholar : PubMed/NCBI
81	Cheuk IW, Shin VY, Siu MT, Tsang JY, Ho JC, Chen J, Tse GM, Wang X and Kwong A: Association of EP2 receptor and SLC19A3 in regulating breast cancer metastasis. Am J Cancer Res. 5:3389–3399. 2015.
82	Kim KM, Im AR, Kim SH, Hyun JW and Chae S: Timosaponin AIII inhibits melanoma cell migration by suppressing COX-2 and in vivo tumor metastasis. Cancer Sci. 107:181–188. 2016. View Article : Google Scholar :
83	Rundhaug JE, Simper MS, Surh I and Fischer SM: The role of the EP receptors for prostaglandin E2 in skin and skin cancer. Cancer Metastasis Rev. 30:465–480. 2011. View Article : Google Scholar : PubMed/NCBI
84	Rundhaug JE and Fischer SM: Cyclo-oxygenase-2 plays a critical role in UV-induced skin carcinogenesis. Photochem Photobiol. 84:322–329. 2008. View Article : Google Scholar : PubMed/NCBI
85	Singh T, Vaid M, Katiyar N, Sharma S and Katiyar SK: Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclo-oxygenase-2, prostaglandin E₂ and prostaglandin E₂ receptors. Carcinogenesis. 32:86–92. 2011. View Article : Google Scholar
86	Mochocki M, Morawski P, Kopta R, Brzezinska-Blaszczyk E, Stasikowska O, Lewy-Trenda I; Student Scientific Circle; Starska K: Expression of prostaglandin E2 prostanoid receptor EP2 and interleukin-1β in laryngeal carcinoma-preliminary study. Contemp Oncol (Pozn). 19:113–119. 2015.
87	Cantaut-Belarif Y, Antri M, Pizzarelli R, Colasse S, Vaccari I, Soares S, Renner M, Dallel R, Triller A and Bessis A: Microglia control the glycinergic but not the GABAergic synapses via prostaglandin E2 in the spinal cord. J Cell Biol. 216:2979–2989. 2017.PubMed/NCBI
88	de Almeida VH, de Melo AC, Meira DD, Pires AC, Nogueira-Rodrigues A, Pimenta-Inada HK, Alves FG, Moralez G, Thiago LS, Ferreira CG and Sternberg C: Radiotherapy modulates expression of EGFR, ERCC1 and p53 in cervical cancer. Braz J Med Biol Res. 51:e68222017. View Article : Google Scholar : PubMed/NCBI
89	Ochoa MC, Minute L, López A4, Pérez-Ruiz E, Gomar C, Vasquez M, Inoges S, Etxeberria I, Rodriguez I, Garasa S, et al: Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15. Oncoimmunology. 7:e13935972017. View Article : Google Scholar
90	Chen A, Ali N, Boasberg P and Ho AS: Clinical remission of cutaneous squamous cell carcinoma of the auricle with cetuximab and nivolumab. J Clin Med. 7:pii: E10. 2018. View Article : Google Scholar
91	Fernández-Martínez AB and Lucio-Cazaña J: Intracellular EP2 prostanoid receptor promotes cancer-related phenotypes in PC3 cells. Cell Mol Life Sci. 72:3355–3373. 2015. View Article : Google Scholar : PubMed/NCBI
92	López Bernal A, Rivera J, Europe-Finner GN, Phaneuf S and Asbóth G: Parturition: Activation of stimulatory pathways or loss of uterine quiescence? Adv Exp Med Biol. 395:435–451. 1995.PubMed/NCBI
93	Brocard E, Oizel K, Lalier L, Pecqueur C, Paris F, Vallette FM and Oliver L: Radiation-induced PGE2 sustains human glioma cells growth and survival through EGF signaling. Oncotarget. 6:6840–6849. 2015. View Article : Google Scholar : PubMed/NCBI
94	Schmidt A, Sinnett-Smith J, Young S, Chang HH, Hines OJ, Dawson DW, Rozengurt E and Eibl G: Direct growth-inhibitory effects of prostaglandin E2 in pancreatic cancer cells in vitro through an EP4/PKA-mediated mechanism. Surgery. 161:1570–1578. 2017. View Article : Google Scholar : PubMed/NCBI
95	Vaid M, Singh T, Prasad R, Kappes JC and Katiyar SK: Therapeutic intervention of proanthocyanidins on the migration capacity of melanoma cells is mediated through PGE2 receptors and β-catenin signaling molecules. Am J Cancer Res. 5:3325–3338. 2015.
96	Chang HH, Young SH, Sinnett-Smith J, Chou CE, Moro A, Hertzer KM, Hines OJ, Rozengurt E and Eibl G: Prostaglandin E2 activates the mTORC1 pathway through an EP4/cAMP/PKA- and EP1/Ca2+-mediated mechanism in the human pancreatic carcinoma cell line PANC-1. Am J Physiol Cell Physiol. 309:C639–C649. 2015. View Article : Google Scholar : PubMed/NCBI
97	Chun KS, Lao HC, Trempus CS, Okada M and Langenbach R: The prostaglandin receptor EP2 activates multiple signaling pathways and beta-arrestin1 complex formation during mouse skin papilloma development. Carcinogenesis. 30:1620–1627. 2009. View Article : Google Scholar : PubMed/NCBI
98	Shu J, Zhang F, Zhang L and Wei W: G protein coupled receptors signaling pathways implicate in inflammatory and immune response of rheumatoid arthritis. Inflamm Res. 66:379–387. 2017. View Article : Google Scholar
99	Yun SP, Ryu JM, Jang MW and Han HJ: Interaction of profilin-1 and F-actin via a β-arrestin-1/JNK signaling pathway involved in prostaglandin E(2)-induced human mesenchymal stem cells migration and proliferation. J Cell Physiol. 226:559–571. 2011. View Article : Google Scholar
100	Narumiya S, Sugimoto Y and Ushikubi F: Prostanoid receptors: Structures, properties, and functions. Physiol Rev. 79:1193–1226. 1999. View Article : Google Scholar : PubMed/NCBI
101	Ganesh T: Prostanoid receptor EP2 as a therapeutic target. J Med Chem. 57:4454–4465. 2014. View Article : Google Scholar :
102	Tani K, Naganawa A, Ishida A, Egashira H, Sagawa K, Harada H, Ogawa M, Maruyama T, Ohuchida S, Nakai H, et al: Design and synthesis of a highly selective EP2-receptor agonist. Bioorg Med Chem Lett. 11:2025–2028. 2001. View Article : Google Scholar : PubMed/NCBI
103	Jadhav V, Jabre A, Lin SZ and Lee TJ: EP1- and EP3-receptors mediate prostaglandin E2-induced constriction of porcine large cerebral arteries. J Cereb Blood Flow Metab. 24:1305–1316. 2004. View Article : Google Scholar : PubMed/NCBI
104	Tani K, Naganawa A, Ishida A, Sagawa K, Harada H, Ogawa M, Maruyama T, Ohuchida S, Nakai H, Kondo K and Toda M: Development of a highly selective EP2-receptor agonist. Part 1: Identification of 16-hydroxy-17, 17-trimethylene PGE2 derivatives. Bioorg Med Chem. 10:1093–1106. 2002. View Article : Google Scholar : PubMed/NCBI
105	Markovič T, Jakopin Ž, Dolenc MS and Mlinarič-Raščan I: Structural features of subtype-selective EP receptor modulators. Drug Discov Today. 22:57–71. 2017. View Article : Google Scholar
106	Yeo HS, Shehzad A and Lee YS: Prostaglandin E2 blocks menadione-induced apoptosis through the Ras/Raf/Erk signaling pathway in promonocytic leukemia cell lines. Mol Cells. 33:371–378. 2012. View Article : Google Scholar : PubMed/NCBI
107	Tanné B, Bernier S and Dumais N: CCR7 receptor expression in Mono-MAC-1 cells: modulation by liver X receptor α activation and prostaglandin E 2. Int J Inflam. 2015:2015712015. View Article : Google Scholar
108	Takahashi HK, Liu K, Wake H, Mori S, Zhang J, Liu R, Yoshino T and Nishibori M: Prostaglandin E2 inhibits advanced glycation end product-induced adhesion molecule expression, cytokine production, and lymphocyte proliferation in human peripheral blood mononuclear cells. J Pharmacol Exp Ther. 331:656–670. 2009. View Article : Google Scholar : PubMed/NCBI
109	Wang R, Zhang W, Dong Z, Qi Y, Hultström M, Zhou X and Lai EY: c-Jun N-terminal Kinase mediates prostaglandin-induced sympathoexcitation in rats with chronic heart failure by reducing GAD1 and GABRA1 expression. Acta Physiol (Oxf). 219:494–509. 2017. View Article : Google Scholar
110	Cameron KO, Lefker BA, Ke HZ, Li M, Zawistoski MP, Tjoa CM, Wright AS, DeNinno SL, Paralkar VM, Owen TA, et al: Discovery of CP-533536: An EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation. Bioorg Med Chem Lett. 19:2075–2078. 2009. View Article : Google Scholar : PubMed/NCBI
111	Säfholm J, Dahlén SE and Adner M: Antagonising EP1 and EP2 receptors reveal that the TP receptor mediates a component of antigen-induced contraction of the guinea pig trachea. Eur J Pharmacol. 718:277–282. 2013. View Article : Google Scholar : PubMed/NCBI
112	Yan G, Wang Q, Shi H, Han Y, Ma G, Tang C and Gu Y: Regulation of rat intrapulmonary arterial tone by arachidonic acid and prostaglandin E2 during hypoxia. PLoS One. 8:e738392013. View Article : Google Scholar : PubMed/NCBI
113	Kay LJ, Gilbert M, Pullen N, Skerratt S, Farrington J, Seward EP and Peachell PT: Characterization of the EP receptor subtype that mediates the inhibitory effects of prostaglandin E2 on IgE-dependent secretion from human lung mast cells. Clin Exp Allergy. 43:741–751. 2013. View Article : Google Scholar : PubMed/NCBI
114	af Forselles KJ, Root J, Clarke T, Davey D, Aughton K, Dack K and Pullen N: In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP2 receptor antagonist. Br J Pharmacol. 164:1847–1856. 2011. View Article : Google Scholar : PubMed/NCBI
115	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45(W1): W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI